Clinical Trial Update: A Phase I/II Study to Evaluate AZD5851 in GPC3+ Advanced/Recurrent Hepatocellular Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating AZD5851 in GPC3-positive advanced or recurrent hepatocellular carcinoma, with the study currently active but not recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• AZD5851

Snippet

Sponsor: AstraZeneca | Conditions: Hepatocellular Carcinoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING